Global metastatic cancer treatment market was valued US$ 54.2 Bn in 2017 and is expected to reach US$ 96.4 Bn by 2026, at a CAGR of 7.46 % during a forecast period.
Metastatic cancer cells are spread from the place where they first formed and travel through the blood or lymph system, and form new metastatic tumors in other parts of the body.
Symptoms of metastatic cancer:
When cancer has spread to the bone pain and fractures are occurred
A headache, seizures, and dizziness have occurred when cancer has spread to the brain.
When cancer has spread to the lung, the problem arises like shortness of breath.
Jaundice and swelling in the belly are formed when cancer has spread to the liver.
The rising prevalence of cancer, increasing prevalence & awareness about metastatic cancer, and growing R&D in the field of oncology is the driving factors of the metastatic cancer treatment market. The rising aging population, advancements in research & development, and promised potential of alternative therapies are boosting the market growth. Adverse side effects of chemotherapy & reimbursement issue are limiting the growth of metastatic cancer treatment market.
Melanoma cancer occurs when the pigment-producing cells that give color to the skin become cancerous and it is a most dangerous form of skin cancer. Melanomas cancer can occur anywhere on the body. The frequency of melanoma appears to be growing for people under the age of 40 years, mainly women.
Generic medicines contain a similar active ingredient in the similar quantity as a brand-name medicine and are anticipated to grow at a significant rate owing to the generic medicines as effective & safe as brand-name medicines. Brand-name medicines are originally discovered, developed, and commercialized by a pharmaceutical company.
Elderly people, changes in lifestyle, recovering publicity to cancer-causing mutagens & other genetic factors, are some of the common risk factors associated with the economic development and epidemiologic transition of the Asia-Pacific region. North America is the leading contributing region to the global metastatic cancer treatment market owing to the presence of wide numbers of research & production hubs of several conglomerate pharmaceuticals & contract research organizations in countries of North America.
Key player operating in global metastatic cancer treatment market are AbbVie, Inc., Amgen, Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, BRISTOL-MYERS SQUIBB COMPANY, CELGENE CORPORATION, Eli-Lilly and Company, F. Hoffmann-La Roche AG, JOHNSON & JOHNSON, Merck & Co., Inc., Novartis AG, Pfizer, Inc., SANOFI, Takeda Pharmaceutical Company Limited, Bluebird bio, Inc., Clovis Oncology, Inc., IDERA PHARMACEUTICALS, INC., and eTheRNA immunotherapies NV.
The Scope of Global Metastatic Cancer Treatment Market:
Global Metastatic Cancer Treatment Market, by Therapeutic indications:
Breast cancer
Prostate cancer
Lung cancer
Melanoma
Colorectal cancer
Other therapeutic applications
Global Metastatic Cancer Treatment Market, by Products:
Branded medicines
Generic medicines
Global Metastatic Cancer Treatment Market, by Region:
North America
Europe
Asia Pacific
South America
Middle East & Africa
Key Player Operating in Global Metastatic Cancer Treatment Market:
AbbVie, Inc.
Amgen, Inc.
AstraZeneca PLC
Bayer AG
Boehringer Ingelheim International GmbH
BRISTOL-MYERS SQUIBB COMPANY
CELGENE CORPORATION
Eli-Lilly and Company
F. Hoffmann-La Roche AG
JOHNSON & JOHNSON
Merck & Co., Inc.
Novartis AG
Pfizer, Inc.
SANOFI
Takeda Pharmaceutical Company Limited
Bluebird bio, Inc.
Clovis Oncology, Inc.
IDERA PHARMACEUTICALS, INC.
eTheRNA immunotherapies NV
Global Metastatic Cancer Treatment Market
1. Preface
1.1. Research Objectives
1.2. Report Scope and Market Segmentation
2. Assumptions and Research Methodology
2.1. Abbreviations
3. Executive Summary
3.1. Global Metastatic Cancer Treatment Market Size, by Market Value (US$ Bn) and Market
4. Market Overview
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers and Restraints Snapshot Analysis
4.2.2. Drivers
4.2.3. Restraints
4.2.4. Opportunities
4.2.5. Porter’s Analysis
4.2.6. Value Chain Analysis
4.2.7. SWOT Analysis
5. Global Metastatic Cancer Treatment Market Analysis and Forecast
5.1. Global Metastatic Cancer Treatment Market Size& Y-o-Y Growth Analysis
5.1.1. North America
5.1.2. Europe
5.1.3. Asia Pacific
5.1.4. Middle East & Africa
5.1.5. South America
6. Global Metastatic Cancer Treatment Market Analysis and Forecast, by Therapeutic indications
6.1. Introduction and Definition
6.2. Global Metastatic Cancer Treatment Market Value Share Analysis, by Therapeutic indications
6.3. Global Metastatic Cancer Treatment Market Size (US$ Bn) Forecast, by Therapeutic indications
6.4. Global Metastatic Cancer Treatment Market Analysis, by Therapeutic indications
6.5. Global Metastatic Cancer Treatment Market Attractiveness Analysis, by Therapeutic indications
6.6. Key Trends
6.6.1. Key Developments
7. Global Metastatic Cancer Treatment Market Analysis and Forecast, by Products
7.1. Introduction and Definition
7.2. Global Metastatic Cancer Treatment Market Value Share Analysis, by Products
7.3. Global Metastatic Cancer Treatment Market Size (US$ Bn) Forecast, by Products
7.4. Global Metastatic Cancer Treatment Market Analysis, by Products
7.5. Global Metastatic Cancer Treatment Market Attractiveness Analysis, by Products
7.6. Key Trends
7.6.1. Key Developments
8. Global Metastatic Cancer Treatment Market Analysis, by Region
8.1. Global Metastatic Cancer Treatment Market Value Share Analysis, by Region
8.2. Global Metastatic Cancer Treatment Market Size (US$ Bn) Forecast, by Region
8.3. Global Metastatic Cancer Treatment Market Attractiveness Analysis, by Region
8.4. Key Trends
8.4.1. Key Developments
9. North America Metastatic Cancer Treatment Market Analysis
9.1. North America Metastatic Cancer Treatment Market Overview
9.2. North America Metastatic Cancer Treatment Market Value Share Analysis, by Therapeutic indications
9.3. North America Metastatic Cancer Treatment Market Forecast, by Therapeutic indications
9.3.1. Breast cancer
9.3.2. Prostate cancer
9.3.3. Lung cancer
9.3.4. Melanoma
9.3.5. Colorectal cancer
9.3.6. Other therapeutic applications
9.4. North America Metastatic Cancer Treatment Market Value Share Analysis, by Products
9.5. North America Metastatic Cancer Treatment Market Forecast, by Products
9.5.1. Branded medicines
9.5.2. Generic medicines
9.6. North America Metastatic Cancer Treatment Market Value Share Analysis, by Country
9.7. North America Metastatic Cancer Treatment Market Forecast, by Country
9.7.1. U.S.
9.7.2. Canada
9.8. North America Metastatic Cancer Treatment Market Analysis, by Country
9.9. U.S. Metastatic Cancer Treatment Market Forecast, by Therapeutic indications
9.9.1. Breast cancer
9.9.2. Prostate cancer
9.9.3. Lung cancer
9.9.4. Melanoma
9.9.5. Colorectal cancer
9.9.6. Other therapeutic applications
9.10. U.S. Metastatic Cancer Treatment Market Forecast, by Products
9.10.1. Branded medicines
9.10.2. Generic medicines
9.11. Canada Metastatic Cancer Treatment Market Forecast, by Therapeutic indications
9.11.1. Breast cancer
9.11.2. Prostate cancer
9.11.3. Lung cancer
9.11.4. Melanoma
9.11.5. Colorectal cancer
9.11.6. Other therapeutic applications
9.12. Canada Metastatic Cancer Treatment Market Forecast, by Products
9.12.1. Branded medicines
9.12.2. Generic medicines
9.13. North America Metastatic Cancer Treatment Market Attractiveness Analysis
9.13.1. By Therapeutic indications
9.13.2. By Products
9.14. PEST Analysis
9.15. Key Trends
9.15.1. Key Developments
10. Europe Metastatic Cancer Treatment Market Analysis
10.1. Europe Metastatic Cancer Treatment Market Overview
10.2. Europe Metastatic Cancer Treatment Market Value Share Analysis, by Therapeutic indications
10.3. Europe Metastatic Cancer Treatment Market Forecast, by Therapeutic indications
10.3.1. Breast cancer
10.3.2. Prostate cancer
10.3.3. Lung cancer
10.3.4. Melanoma
10.3.5. Colorectal cancer
10.3.6. Other therapeutic applications
10.4. Europe Metastatic Cancer Treatment Market Value Share Analysis, by Products
10.5. Europe Metastatic Cancer Treatment Market Forecast, by Products
10.5.1. Branded medicines
10.5.2. Generic medicines
10.6. Europe Metastatic Cancer Treatment Market Value Share Analysis, by Country
10.7. Europe Metastatic Cancer Treatment Market Forecast, by Country
10.7.1. Germany
10.7.2. U.K.
10.7.3. France
10.7.4. Italy
10.7.5. Spain
10.7.6. Rest of Europe
10.8. Europe Metastatic Cancer Treatment Market Analysis, by Country/ Sub-region
10.9. Germany Metastatic Cancer Treatment Market Forecast, by Therapeutic indications
10.9.1. Breast cancer
10.9.2. Prostate cancer
10.9.3. Lung cancer
10.9.4. Melanoma
10.9.5. Colorectal cancer
10.9.6. Other therapeutic applications
10.10. Germany Metastatic Cancer Treatment Market Forecast, by Products
10.10.1. Branded medicines
10.10.2. Generic medicines
10.11. U.K. Metastatic Cancer Treatment Market Forecast, by Therapeutic indications
10.11.1. Breast cancer
10.11.2. Prostate cancer
10.11.3. Lung cancer
10.11.4. Melanoma
10.11.5. Colorectal cancer
10.11.6. Other therapeutic applications
10.12. U.K. Metastatic Cancer Treatment Market Forecast, by Products
10.12.1. Branded medicines
10.12.2. Generic medicines
10.13. France Metastatic Cancer Treatment Market Forecast, by Therapeutic indications
10.13.1. Breast cancer
10.13.2. Prostate cancer
10.13.3. Lung cancer
10.13.4. Melanoma
10.13.5. Colorectal cancer
10.13.6. Other therapeutic applications
10.14. France Metastatic Cancer Treatment Market Forecast, by Products
10.14.1. Branded medicines
10.14.2. Generic medicines
10.15. Italy Metastatic Cancer Treatment Market Forecast, by Therapeutic indications
10.15.1. Breast cancer
10.15.2. Prostate cancer
10.15.3. Lung cancer
10.15.4. Melanoma
10.15.5. Colorectal cancer
10.15.6. Other therapeutic applications
10.16. Italy Metastatic Cancer Treatment Market Forecast, by Products
10.16.1. Branded medicines
10.16.2. Generic medicines
10.17. Spain Metastatic Cancer Treatment Market Forecast, by Therapeutic indications
10.17.1. Breast cancer
10.17.2. Prostate cancer
10.17.3. Lung cancer
10.17.4. Melanoma
10.17.5. Colorectal cancer
10.17.6. Other therapeutic applications
10.18. Spain Metastatic Cancer Treatment Market Forecast, by Products
10.18.1. Branded medicines
10.18.2. Generic medicines
10.19. Rest of Europe Metastatic Cancer Treatment Market Forecast, by Therapeutic indications
10.19.1. Breast cancer
10.19.2. Prostate cancer
10.19.3. Lung cancer
10.19.4. Melanoma
10.19.5. Colorectal cancer
10.19.6. Other therapeutic applications
10.20. Rest of Europe Metastatic Cancer Treatment Market Forecast, by Products
10.20.1. Branded medicines
10.20.2. Generic medicines
10.21. Europe Metastatic Cancer Treatment Market Attractiveness Analysis
10.21.1. By Therapeutic indications
10.21.2. By Products
10.22. PEST Analysis
10.23. Key Trends
10.23.1. Key Developments
11. Asia Pacific Metastatic Cancer Treatment Market Analysis
11.1. Key Findings
11.2. Asia Pacific Metastatic Cancer Treatment Market Overview
11.3. Asia Pacific Metastatic Cancer Treatment Market Value Share Analysis, by Therapeutic indications
11.4. Asia Pacific Metastatic Cancer Treatment Market Forecast, by Therapeutic indications
11.4.1. Breast cancer
11.4.2. Prostate cancer
11.4.3. Lung cancer
11.4.4. Melanoma
11.4.5. Colorectal cancer
11.4.6. Other therapeutic applications
11.5. Asia Pacific Metastatic Cancer Treatment Market Value Share Analysis, by Products
11.6. Asia Pacific Metastatic Cancer Treatment Market Forecast, by Products
11.6.1. Branded medicines
11.6.2. Generic medicines
11.7. Asia Pacific Metastatic Cancer Treatment Market Value Share Analysis, by Country
11.8. Asia Pacific Metastatic Cancer Treatment Market Forecast, by Country
11.8.1. China
11.8.2. India
11.8.3. Japan
11.8.4. ASEAN
11.8.5. Rest of Asia Pacific
11.9. Asia Pacific Metastatic Cancer Treatment Market Analysis, by Country/ Sub-region
11.10. China Metastatic Cancer Treatment Market Forecast, by Therapeutic indications
11.10.1. Breast cancer
11.10.2. Prostate cancer
11.10.3. Lung cancer
11.10.4. Melanoma
11.10.5. Colorectal cancer
11.10.6. Other therapeutic applications
11.11. China Metastatic Cancer Treatment Market Forecast, by Products
11.11.1. Branded medicines
11.11.2. Generic medicines
11.12. India Metastatic Cancer Treatment Market Forecast, by Therapeutic indications
11.12.1. Breast cancer
11.12.2. Prostate cancer
11.12.3. Lung cancer
11.12.4. Melanoma
11.12.5. Colorectal cancer
11.12.6. Other therapeutic applications
11.13. India Metastatic Cancer Treatment Market Forecast, by Products
11.13.1. Branded medicines
11.13.2. Generic medicines
11.14. Japan Metastatic Cancer Treatment Market Forecast, by Therapeutic indications
11.14.1. Breast cancer
11.14.2. Prostate cancer
11.14.3. Lung cancer
11.14.4. Melanoma
11.14.5. Colorectal cancer
11.14.6. Other therapeutic applications
11.15. Japan Metastatic Cancer Treatment Market Forecast, by Products
11.15.1. Branded medicines
11.15.2. Generic medicines
11.16. ASEAN Metastatic Cancer Treatment Market Forecast, by Therapeutic indications
11.16.1. Breast cancer
11.16.2. Prostate cancer
11.16.3. Lung cancer
11.16.4. Melanoma
11.16.5. Colorectal cancer
11.16.6. Other therapeutic applications
11.17. ASEAN Metastatic Cancer Treatment Market Forecast, by Products
11.17.1. Branded medicines
11.17.2. Generic medicines
11.18. Rest of Asia Pacific Metastatic Cancer Treatment Market Forecast, by Therapeutic indications
11.18.1. Breast cancer
11.18.2. Prostate cancer
11.18.3. Lung cancer
11.18.4. Melanoma
11.18.5. Colorectal cancer
11.18.6. Other therapeutic applications
11.19. Rest of Asia Pacific Metastatic Cancer Treatment Market Forecast, by Products
11.19.1. Branded medicines
11.19.2. Generic medicines
11.20. Asia Pacific Metastatic Cancer Treatment Market Attractiveness Analysis
11.20.1. By Therapeutic indications
11.20.2. By Products
11.21. PEST Analysis
11.22. Key Trends
11.22.1. Key Developments
12. Middle East & Africa Metastatic Cancer Treatment Market Analysis
12.1. Key Findings
12.2. Middle East & Africa Metastatic Cancer Treatment Market Overview
12.3. Middle East & Africa Metastatic Cancer Treatment Market Value Share Analysis, by Therapeutic indications
12.4. Middle East & Africa Metastatic Cancer Treatment Market Forecast, by Therapeutic indications
12.4.1. Breast cancer
12.4.2. Prostate cancer
12.4.3. Lung cancer
12.4.4. Melanoma
12.4.5. Colorectal cancer
12.4.6. Other therapeutic applications
12.5. Middle East & Africa Metastatic Cancer Treatment Market Value Share Analysis, by Products
12.6. Middle East & Africa Metastatic Cancer Treatment Market Forecast, by Products
12.6.1. Branded medicines
12.6.2. Generic medicines
12.7. Middle East & Africa Metastatic Cancer Treatment Market Value Share Analysis, by Country
12.8. Middle East & Africa Metastatic Cancer Treatment Market Forecast, by Country
12.8.1. GCC
12.8.2. South Africa
12.8.3. Rest of Middle East & Africa
12.9. Middle East & Africa Metastatic Cancer Treatment Market Analysis, by Country/ Sub-region
12.10. GCC Metastatic Cancer Treatment Market Forecast, by Therapeutic indications
12.10.1. Breast cancer
12.10.2. Prostate cancer
12.10.3. Lung cancer
12.10.4. Melanoma
12.10.5. Colorectal cancer
12.10.6. Other therapeutic applications
12.11. GCC Metastatic Cancer Treatment Market Forecast, by Products
12.11.1. Branded medicines
12.11.2. Generic medicines
12.12. South Africa Metastatic Cancer Treatment Market Forecast, by Therapeutic indications
12.12.1. Breast cancer
12.12.2. Prostate cancer
12.12.3. Lung cancer
12.12.4. Melanoma
12.12.5. Colorectal cancer
12.12.6. Other therapeutic applications
12.13. South Africa Metastatic Cancer Treatment Market Forecast, by Products
12.13.1. Branded medicines
12.13.2. Generic medicines
12.14. Rest of Middle East & Africa Metastatic Cancer Treatment Market Forecast, by Therapeutic indications
12.14.1. Breast cancer
12.14.2. Prostate cancer
12.14.3. Lung cancer
12.14.4. Melanoma
12.14.5. Colorectal cancer
12.14.6. Other therapeutic applications
12.15. Rest of Middle East & Africa Metastatic Cancer Treatment Market Forecast, by Products
12.15.1. Branded medicines
12.15.2. Generic medicines
12.16. Middle East & Africa Metastatic Cancer Treatment Market Attractiveness Analysis
12.16.1. By Therapeutic indications
12.16.2. By Products
12.17. PEST Analysis
12.18. Key Trends
12.18.1. Key Developments
13. South America Metastatic Cancer Treatment Market Analysis
13.1. Key Findings
13.2. South America Metastatic Cancer Treatment Market Overview
13.3. South America Metastatic Cancer Treatment Market Value Share Analysis, by Therapeutic indications
13.4. South America Metastatic Cancer Treatment Market Forecast, by Therapeutic indications
13.4.1. Breast cancer
13.4.2. Prostate cancer
13.4.3. Lung cancer
13.4.4. Melanoma
13.4.5. Colorectal cancer
13.4.6. Other therapeutic applications
13.5. South America Metastatic Cancer Treatment Market Value Share Analysis, by Products
13.6. South America Metastatic Cancer Treatment Market Forecast, by Products
13.6.1. Branded medicines
13.6.2. Generic medicines
13.7. South America Metastatic Cancer Treatment Market Value Share Analysis, by Country
13.8. South America Metastatic Cancer Treatment Market Forecast, by Country
13.8.1. Brazil
13.8.2. Mexico
13.8.3. Rest of South America
13.9. South America Metastatic Cancer Treatment Market Analysis, by Country/ Sub-region
13.10. Brazil Metastatic Cancer Treatment Market Forecast, by Therapeutic indications
13.10.1. Breast cancer
13.10.2. Prostate cancer
13.10.3. Lung cancer
13.10.4. Melanoma
13.10.5. Colorectal cancer
13.10.6. Other therapeutic applications
13.11. Brazil Metastatic Cancer Treatment Market Forecast, by Products
13.11.1. Branded medicines
13.11.2. Generic medicines
13.12. Mexico Metastatic Cancer Treatment Market Forecast, by Therapeutic indications
13.12.1. Breast cancer
13.12.2. Prostate cancer
13.12.3. Lung cancer
13.12.4. Melanoma
13.12.5. Colorectal cancer
13.12.6. Other therapeutic applications
13.13. Mexico Metastatic Cancer Treatment Market Forecast, by Products
13.13.1. Branded medicines
13.13.2. Generic medicines
13.14. Rest of South America Metastatic Cancer Treatment Market Forecast, by Therapeutic indications
13.14.1. Breast cancer
13.14.2. Prostate cancer
13.14.3. Lung cancer
13.14.4. Melanoma
13.14.5. Colorectal cancer
13.14.6. Other therapeutic applications
13.15. Rest of South America Metastatic Cancer Treatment Market Forecast, by Products
13.15.1. Branded medicines
13.15.2. Generic medicines
13.16. South America Metastatic Cancer Treatment Market Attractiveness Analysis
13.16.1. By Therapeutic indications
13.16.2. By Products
13.17. PEST Analysis
13.18. Key Trends
13.18.1. Key Developments
14. Competitive Landscape
14.1. Market Share Analysis, by Company
14.2. Competition Matrix
14.3. Competitive Benchmarking of Company and Services
14.4. Company Profiles: Key Players
14.4.1. AbbVie, Inc.
14.4.1.1. Company Overview
14.4.1.2. Financial Overview
14.4.1.3. Business Strategy
14.4.1.4. Recent Developments
14.4.1.5. Development Footprint
14.4.2. Amgen, Inc.
14.4.3. AstraZeneca PLC
14.4.4. Bayer AG
14.4.5. Boehringer Ingelheim International GmbH
14.4.6. BRISTOL-MYERS SQUIBB COMPANY
14.4.7. CELGENE CORPORATION
14.4.8. Eli-Lilly and Company
14.4.9. F. Hoffmann-La Roche AG
14.4.10. JOHNSON & JOHNSON
14.4.11. Merck & Co., Inc.
14.4.12. Novartis AG
14.4.13. Pfizer, Inc.
14.4.14. SANOFI
14.4.15. Takeda Pharmaceutical Company Limited
14.4.16. Bluebird bio, Inc.
14.4.17. Clovis Oncology, Inc.
14.4.18. IDERA PHARMACEUTICALS, INC.
14.4.19. eTheRNA immunotherapies NV
15. Primary Key Insights
